Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib
Pre-publication versions of this article are available by contacting email@example.com.
|7 Oct 2015||Submitted||Original manuscript|
|7 Nov 2015||Reviewed||Reviewer Report - Yusuke Okuma|
|8 Nov 2015||Reviewed||Reviewer Report - Chang-Hsien Lu|
|8 Dec 2015||Author responded||Author comments - Victor Lee|
|Resubmission - Version 2|
|8 Dec 2015||Submitted||Manuscript version 2|
|22 Jan 2016||Author responded||Author comments - Victor Lee|
|Resubmission - Version 3|
|22 Jan 2016||Submitted||Manuscript version 3|
|6 Feb 2016||Author responded||Author comments - Victor Lee|
|Resubmission - Version 4|
|6 Feb 2016||Submitted||Manuscript version 4|
|17 Feb 2016||Editorially accepted|
|24 Feb 2016||Article published||10.1186/s12885-016-2201-9|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.